Regorafenib as Salvage Treatment in Korean Patients with Refractory Metastatic Colorectal Cancer

PURPOSE: Regorafenib, an oral multi-targeted tyrosine kinase inhibitor, is considered the new standard of care in patients with chemotherapy-refractory colorectal cancers (CRCs). However, there are no data on this drug in Korean patients. MATERIALS AND METHODS: We evaluated patients who received ora...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Cancer Res Treat
Hlavní autoři: Kim, Seung Tae, Kim, Tae Won, Kim, Kyu-pyo, Kim, Tae-You, Han, Sae-Won, Lee, Ji Yun, Lim, Sung Hee, Lee, Min-Young, Kim, Haesu, Park, Young Suk
Médium: Artigo
Jazyk:Inglês
Vydáno: Korean Cancer Association 2015
Témata:
Original Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4614225/
https://ncbi.nlm.nih.gov/pubmed/25672574
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4143/crt.2014.126
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky